- Fecal Incontinence
This activity has been designed to meet the educational needs of gastroenterologists, physician assistants, and nurse practitioners involved in the management of IBD
Upon completion of this activity, participants should be better able to:
Describe the latest advances in basic/translational science in the management of IBD
Identify new evidence on the impact of therapeutic monitoring on short- and long-term outcomes
Discuss new data on potential adverse events of IBD therapy
Discuss the design and results of recent clinical trials in IBD for both established therapies and new therapies
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Purdue University College of Pharmacy and the Gi Health Foundation. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University College of Pharmacy designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release Date: August 25, 2014Expiration Date: August 25, 2015 EXPIRED
Physician Disclosure Statement
All faculty and staff involved in the planning or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. The Gi Health Foundation staff and Purdue University College of Pharmacy staff have no relationships to disclose.
This material is supported by educational grants from AbbVie, Janssen Biotech Inc., Takeda Pharmaceuticals International, Inc., US Region and Prometheus Pharmaceuticals.